Urologic Imaging

What Imaging Is Best for Hematospermia in Men Over 40 or with Persistent Symptoms?

·
What Imaging Is Best for Hematospermia in Men Over 40 or with Persistent Symptoms?

A 52-year-old man sits in your exam room, concerned. He’s noticed blood in his semen for the third time in the last six months, and a quick internet search has him worried about prostate cancer. He has no other urinary symptoms or known risk factors. While hematospermia is often benign, particularly in younger men, his age and the recurrent nature of his symptoms place him in a higher-risk category that warrants a diagnostic workup. The immediate clinical question is which imaging study to order first to evaluate the prostate, seminal vesicles, and adjacent structures. According to the American College of Radiology (ACR) Appropriateness Criteria, for this specific presentation, MRI pelvis without and with IV contrast is rated Usually Appropriate.

Who Fits This Clinical Scenario?

This imaging workflow is designed for a specific subset of patients presenting with hematospermia. The inclusion criteria are precise:

  • Any male patient aged 40 years or older presenting with hematospermia, even a single episode.
  • Any male patient, regardless of age, who experiences persistent or recurrent hematospermia.
  • Any male patient, regardless of age, whose hematospermia is accompanied by associated signs or symptoms of urologic disease. These can include voiding symptoms (hesitancy, frequency, urgency), pelvic pain, constitutional symptoms like weight loss, or an abnormal digital rectal exam (DRE) or prostate-specific antigen (PSA) level.

It is critical to distinguish this group from patients who do not fit this scenario. This guidance does not apply to a young man under 40 who presents with a single, transient episode of hematospermia and has no other signs, symptoms, or risk factors. In that lower-risk scenario, the cause is most often benign and self-limited, and the ACR notes that imaging is typically not warranted as an initial step. Applying this higher-intensity workup to a low-risk patient can lead to unnecessary testing and patient anxiety.

What Diagnoses Are You Working Up in This Scenario?

In patients over 40 or those with persistent symptoms, the primary goal of imaging is to exclude significant underlying pathology. While most cases are still ultimately found to be idiopathic or related to benign inflammation, the differential diagnosis is broader and includes more consequential conditions.

Prostate Cancer: This is often the primary concern for both the patient and the clinician, especially in men over 40. While hematospermia is not a common presenting symptom of prostate cancer, it can occur, particularly with tumors located near the ejaculatory ducts or seminal vesicles. Imaging helps evaluate for suspicious lesions within the prostate gland.

Seminal Vesicle or Ejaculatory Duct Abnormalities: The seminal vesicles and ejaculatory ducts are common sites of pathology leading to hematospermia. Imaging is crucial for identifying obstruction, inflammation (seminal vesiculitis), stones (calculi), or congenital anomalies like Müllerian duct cysts, which can become symptomatic in adulthood.

Benign Prostatic Hyperplasia (BPH) and Prostatitis: Inflammation of the prostate (prostatitis) is a very common cause of hematospermia. The increased vascularity and friable tissue associated with both inflammation and BPH can lead to bleeding. Imaging can reveal secondary signs of these conditions, such as glandular enlargement or inflammatory changes.

Other Urogenital Tumors: Though less common, tumors of the seminal vesicles, bladder, or urethra can also present with hematospermia. Cross-sectional imaging provides a comprehensive evaluation of the entire pelvis to assess for these possibilities.

Why Is MRI Pelvis without and with IV Contrast the Recommended Study?

The ACR designates MRI pelvis without and with IV contrast as Usually Appropriate for this clinical scenario because of its superior ability to visualize the key anatomical structures and differentiate between potential causes without using ionizing radiation.

The exceptional soft-tissue contrast of Magnetic Resonance Imaging (MRI) is its primary advantage. It provides detailed images of the prostate’s zonal anatomy, the seminal vesicles, the ejaculatory ducts, and the bladder wall, which are the most likely sources of pathology. The addition of intravenous (IV) gadolinium-based contrast material is critical. Post-contrast sequences highlight areas of abnormal enhancement, helping to distinguish between inflammatory processes, which often show diffuse enhancement, and malignant tumors, which may demonstrate focal, early enhancement.

Let’s compare this to other modalities rated for this scenario:

  • Transrectal Ultrasound (TRUS) of the prostate: Rated as May be appropriate, TRUS offers excellent high-resolution imaging of the prostate and can guide biopsies. However, its field of view is limited, making it less effective for evaluating the entirety of the seminal vesicles or other extra-prostatic causes. It is also more invasive and operator-dependent than MRI.
  • CT of the pelvis with IV contrast: Also rated as May be appropriate, CT is widely available and fast. However, its soft-tissue resolution is significantly inferior to MRI for evaluating the internal architecture of the prostate and seminal vesicles. Furthermore, it exposes the patient to ionizing radiation (Relative Radiation Level ☢☢☢ 1-10 mSv), whereas MRI has no radiation dose (0 mSv).

The comprehensive, non-irradiating, and highly detailed view offered by a contrast-enhanced pelvic MRI makes it the most effective initial imaging test to confidently assess the wide range of potential causes in this higher-risk patient population.

What’s Next After MRI Pelvis without and with IV Contrast? Downstream Workflow

The results of the pelvic MRI will guide the subsequent clinical pathway. The downstream workflow depends on whether the findings are positive, negative, or indeterminate.

If the MRI is positive for a suspicious lesion:
A finding suspicious for malignancy, such as a PI-RADS 4 or 5 lesion in the prostate, mandates an urgent referral to a urologist. The next steps will typically involve a prostate-specific antigen (PSA) test if not already performed, followed by consideration of a targeted MRI-ultrasound fusion biopsy to obtain a tissue diagnosis.

If the MRI is negative:
A normal MRI is highly reassuring and significantly lowers the probability of a serious underlying cause like cancer. In many cases, the patient can be managed with observation and reassurance that the condition is likely benign and self-limited. If symptoms persist despite a negative MRI, the focus may shift to pathologies not well-visualized on MRI, such as urethritis or subtle bladder lesions. A urology consultation for consideration of cystoscopy may be the appropriate next step.

If the MRI is indeterminate:
Findings such as complex cysts, nonspecific inflammatory changes, or ejaculatory duct dilation may be considered indeterminate. Depending on the specific finding, the next step could be a follow-up MRI to ensure stability, a TRUS for better characterization of a specific prostatic or peri-prostatic finding, or a urology consultation for further clinical correlation and potential endoscopic evaluation.

Pitfalls to Avoid (and When to Get Help)

Navigating the workup for hematospermia requires careful patient stratification and modality selection. Here are a few common pitfalls to avoid:

  • Under-investigating a high-risk patient: Do not mistake a man over 40 or one with recurrent symptoms for the low-risk patient (<40, single episode). Dismissing the need for imaging in this scenario can delay the diagnosis of a significant condition.
  • Ordering a non-contrast MRI: While a non-contrast study is better than nothing, it significantly limits the diagnostic yield. Contrast is essential for characterizing enhancing lesions, which is key to differentiating tumor from inflammation.
  • Forgetting contraindications: Always screen for contraindications to MRI (e.g., incompatible metallic implants) and gadolinium-based contrast agents (e.g., severe renal impairment, history of allergic reaction) before ordering the study.

If the patient presents with concomitant gross hematuria (visible blood in the urine), the workup should be escalated to include evaluation of the entire urinary tract (kidneys, ureters, bladder), often with a CT Urogram (CTU), in addition to the pelvic evaluation.

Related ACR Topics and Tools

This article focuses on one specific clinical variant. For a comprehensive overview of all scenarios related to hematospermia, please consult our parent guide. For additional decision support, the following resources are available:

Frequently Asked Questions

Why not just start with a transrectal ultrasound (TRUS) since it’s faster and cheaper?

While TRUS is rated as ‘May be appropriate’ and is excellent for visualizing the prostate, its field of view is limited. It may not adequately assess the seminal vesicles or other potential extra-prostatic sources of bleeding. Pelvic MRI provides a more comprehensive, global assessment of all potential sources in the pelvis, making it a more robust initial diagnostic test in this higher-risk population.

Is a CT scan an acceptable alternative if MRI is unavailable or contraindicated?

Yes, a CT of the pelvis with IV contrast is rated ‘May be appropriate’ and can be a reasonable alternative if MRI is contraindicated (e.g., due to an incompatible pacemaker) or not readily available. However, it’s important to recognize its limitations in soft-tissue detail for the prostate and seminal vesicles and the fact that it involves ionizing radiation.

What if my patient is over 40 but this is his very first episode of hematospermia?

According to the ACR criteria for this scenario, any male aged 40 or older with hematospermia fits the criteria for initial imaging. The age of 40 is used as a threshold where the pre-test probability of significant pathology, including malignancy, begins to increase, justifying a diagnostic workup even for a single episode.

Does a normal PSA level mean I can skip the MRI?

No. While a normal prostate-specific antigen (PSA) level is reassuring, it does not exclude prostate cancer or other significant pathologies. Some aggressive prostate cancers do not produce significant amounts of PSA. Furthermore, the cause of hematospermia may be unrelated to the prostate (e.g., a seminal vesicle cyst), which would not be detected by a PSA test. The MRI evaluates anatomy, while the PSA is a biochemical marker; they provide complementary information.

What specific ‘associated signs or symptoms’ should prompt imaging in a younger patient with hematospermia?

In a patient under 40, imaging should be considered if hematospermia is accompanied by symptoms like difficulty urinating, pelvic or perineal pain, fever, unexplained weight loss, or if a physical exam reveals an abnormality such as a nodule on digital rectal exam (DRE) or testicular mass. These associated findings raise the suspicion of an underlying structural or inflammatory cause that warrants investigation.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026